LUND, Sweden--(BUSINESS WIRE)--Regulatory News: Probi (STO:PROB) has signed a distribution agreement with Alvogen IPCO S.Á.R.L, a multi-national pharmaceutical company. Alvogen plans to launch Probi’s gut and immune health products on the Taiwanese market in Q1 2013.
“Alvogen is a multi-national company with offices in over 20 countries with ambitious plans for expansion in Asia. Taiwan is a very important market for Alvogen and we are very pleased that they will launch both our consumer healthcare products”, says Michael Oredsson, CEO of Probi.
